On the fly News and insights, exclusive to thefly.com

ATRA

Atara Biotherapeutics

$14.97 /

+1.13 (+8.16%)

, LOW

Lowe's

$199.89 /

+4.36 (+2.23%)

09:53
05/13/21
05/13
09:53
05/13/21
09:53

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) upgraded to Overweight from Neutral at JPMorgan with analyst Anupam Rama saying the most recent U.S. physician survey showed "clear enthusiasm" for ATA188 despite the early stage of the Phase 1 results in progressive multiple sclerosis. 2. Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the upgrade is "largely tactical in nature" and based on the prospects for a continued flow of funds into more cyclically focused equites as well as Lowe's "now historically discounted valuation" versus that of Home Depot (HD). 3. BJ's Wholesale (BJ) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers making a risk/reward call as he sees potential upside to the consensus Q1 comp estimate of down 9%. 4. Pioneer Natural (PXD) upgraded to Overweight from Sector Weight at KeyBanc with analyst Leo Mariani expecting the company's 2021 oil production to come in 1.4% above the high end of its guidance. 5. Ventas (VTR) upgraded to Outperform from Neutral at Baird and upgraded to Overweight from Underweight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ATRA

Atara Biotherapeutics

$14.97 /

+1.13 (+8.16%)

LOW

Lowe's

$199.89 /

+4.36 (+2.23%)

BJ

BJ's Wholesale

$45.75 /

+2.28 (+5.24%)

PXD

Pioneer Natural

$155.33 /

-0.75 (-0.48%)

VTR

Ventas

$53.17 /

+0.98 (+1.88%)

  • 19

    May

  • 20

    May

  • 25

    May

  • 27

    May

  • 28

    May

  • 08

    Jun

  • 08

    Jun

  • 17

    Jun

  • 27

    May

  • 09

    Dec

  • 11

    May

ATRA Atara Biotherapeutics
$14.97 /

+1.13 (+8.16%)

05/13/21 JPMorgan
Atara Biotherapeutics upgraded to Overweight from Neutral at JPMorgan
03/25/21 Evercore ISI
Viracta Therapeutics initiated with an Outperform at Evercore ISI
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy at Citi following 35% pullback
03/02/21 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
LOW Lowe's
$199.89 /

+4.36 (+2.23%)

05/13/21 Oppenheimer
Opco upgrades Lowe's on 'historically discounted valuation' to Home Depot
05/13/21 Oppenheimer
Lowe's upgraded to Outperform from Perform at Oppenheimer
05/05/21 Wells Fargo
Lowe's price target raised to $225 from $210 at Wells Fargo
05/04/21 Citi
Lowe's price target raised to $239 from $195 at Citi
BJ BJ's Wholesale
$45.75 /

+2.28 (+5.24%)

05/13/21 JPMorgan
BJ's Wholesale upgraded on potential Q1 upside at JPMorgan
05/13/21 JPMorgan
BJ's Wholesale upgraded to Overweight from Neutral at JPMorgan
03/16/21 MKM Partners
BJ's Wholesale price target lowered to $39 from $41 at MKM Partners
03/05/21 DA Davidson
BJ's Wholesale price target lowered to $50 from $55 at DA Davidson
PXD Pioneer Natural
$155.33 /

-0.75 (-0.48%)

05/13/21 KeyBanc
KeyBanc upgrades Pioneer Natural on potential guidance upside
05/12/21 KeyBanc
Pioneer Natural upgraded to Overweight from Sector Weight at KeyBanc
05/06/21
Fly Intel: Top five analyst downgrades
05/06/21 Truist
Pioneer Natural downgraded to Hold from Buy at Truist
VTR Ventas
$53.17 /

+0.98 (+1.88%)

05/13/21 Baird
Ventas upgraded to Outperform at Baird
05/13/21 KeyBanc
Ventas upgraded to Overweight from Underweight at KeyBanc
05/13/21 Baird
Ventas upgraded to Outperform from Neutral at Baird
04/08/21 SMBC Nikko
Ventas upgraded to Outperform from Neutral at SMBC Nikko

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.